abstract |
The invention discloses the application of lncRNA in the diagnosis and prognosis prediction of liver cancer. The lncRNA is selected from one or more of TD-2574D22.4, SERHL, MIR100HG, and SNHG20. The invention proves the lncRNA TD-2574D22. 4. SERHL, MIR100HG, and SNHG20 are differentially expressed in liver cancer patients; the present invention also discloses a risk scoring model for predicting the prognosis of liver cancer. According to the model, it can be used as an auxiliary means to predict the prognosis of liver cancer patients, so as to perform risk assessment and monitoring on patients . |